Abstract
Somatic cell nuclear transfer and transcription-factor-based reprogramming revert adult cells to an embryonic state, and yield pluripotent stem cells that can generate all tissues. Through different mechanisms and kinetics, these two reprogramming methods reset genomic methylation, an epigenetic modification of DNA that influences gene expression, leading us to hypothesize that the resulting pluripotent stem cells might have different properties. Here we observe that low-passage induced pluripotent stem cells (iPSCs) derived by factor-based reprogramming of adult murine tissues harbour residual DNA methylation signatures characteristic of their somatic tissue of origin, which favours their differentiation along lineages related to the donor cell, while restricting alternative cell fates. Such an ‘epigenetic memory’ of the donor tissue could be reset by differentiation and serial reprogramming, or by treatment of iPSCs with chromatin-modifying drugs. In contrast, the differentiation and methylation of nuclear-transfer-derived pluripotent stem cells were more similar to classical embryonic stem cells than were iPSCs. Our data indicate that nuclear transfer is more effective at establishing the ground state of pluripotency than factor-based reprogramming, which can leave an epigenetic memory of the tissue of origin that may influence efforts at directed differentiation for applications in disease modelling or treatment.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 51 print issues and online access
$199.00 per year
only $3.90 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout




Similar content being viewed by others
Accession codes
Primary accessions
Gene Expression Omnibus
Data deposits
CHARM microarray data are deposited at the Gene Expression Omnibus (http://www.ncbi.nlm.nih.gov/geo) under accession number GSE22851.
References
Takahashi, K. & Yamanaka, S. Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. Cell 126, 663–676 (2006)
Zhao, X. Y. et al. iPS cells produce viable mice through tetraploid complementation. Nature 461, 86–90 (2009)
Daley, G. Q. et al. Broader implications of defining standards for the pluripotency of iPSCs. Cell Stem Cell 4, 200–201 (2009)
Marión, R. M. et al. A p53-mediated DNA damage response limits reprogramming to ensure iPS cell genomic integrity. Nature 460, 1149–1153 (2009)
Li, H. et al. The Ink4/Arf locus is a barrier for iPS cell reprogramming. Nature 460, 1136–1139 (2009)
Eminli, S. et al. Differentiation stage determines potential of hematopoietic cells for reprogramming into induced pluripotent stem cells. Nature Genet. 41, 968–976 (2009)
Gurdon, J. B. & Melton, D. A. Nuclear reprogramming in cells. Science 322, 1811–1815 (2008)
Blelloch, R. et al. Reprogramming efficiency following somatic cell nuclear transfer is influenced by the differentiation and methylation state of the donor nucleus. Stem Cells 24, 2007–2013 (2006)
Maherali, N. et al. A high-efficiency system for the generation and study of human induced pluripotent stem cells. Cell Stem Cell 3, 340–345 (2008)
Aoi, T. et al. Generation of pluripotent stem cells from adult mouse liver and stomach cells. Science 321, 699–702 (2008)
Miura, K. et al. Variation in the safety of induced pluripotent stem cell lines. Nature Biotechnol. 27, 743–745 (2009)
Chan, E. M. et al. Live cell imaging distinguishes bona fide human iPS cells from partially reprogrammed cells. Nature Biotechnol. 27, 1033–1037 (2009)
Mikkelsen, T. S. et al. Dissecting direct reprogramming through integrative genomic analysis. Nature 454, 49–55 (2008)
Santos, F., Hendrich, B., Reik, W. & Dean, W. Dynamic reprogramming of DNA methylation in the early mouse embryo. Dev. Biol. 241, 172–182 (2002)
Skow, L. C. et al. A mouse model for β-thalassemia. Cell 34, 1043–1052 (1983)
Kyba, M., Perlingeiro, R. C. & Daley, G. Q. HoxB4 confers definitive lymphoid-myeloid engraftment potential on embryonic stem cell and yolk sac hematopoietic progenitors. Cell 109, 29–37 (2002)
Bourne, S., Polak, J. M., Hughes, S. P. & Buttery, L. D. Osteogenic differentiation of mouse embryonic stem cells: differential gene expression analysis by cDNA microarray and purification of osteoblasts by cadherin-11 magnetically activated cell sorting. Tissue Eng. 10, 796–806 (2004)
Wdziekonski, B., Villageois, P. & Dani, C. Differentiation of mouse embryonic stem cells and of human adult stem cells into adipocytes. Curr. Protoc. Cell Biol. 23, 23.24 (2007)
Hood, R. C. & Neill, W. M. A modification of alizarin red S technic for demonstrating bone formation. Stain Technol. 23, 209–218 (1948)
Irizarry, R. A. et al. Comprehensive high-throughput arrays for relative methylation (CHARM). Genome Res. 18, 780–790 (2008)
Irizarry, R. A. et al. The human colon cancer methylome shows similar hypo- and hypermethylation at conserved tissue-specific CpG island shores. Nature Genet. 41, 178–186 (2009)
Doi, A. et al. Differential methylation of tissue- and cancer-specific CpG island shores distinguishes human induced pluripotent stem cells, embryonic stem cells and fibroblasts. Nature Genet. 41, 1350–1353 (2009)
Turker, M. S. Gene silencing in mammalian cells and the spread of DNA methylation. Oncogene 21, 5388–5393 (2002)
Perez-Iratxeta, C. et al. Study of stem cell function using microarray experiments. FEBS Lett. 579, 1795–1801 (2005)
Kim, J., Chu, J., Shen, X., Wang, J. & Orkin, S. H. An extended transcriptional network for pluripotency of embryonic stem cells. Cell 132, 1049–1061 (2008)
Wernig, M. et al. In vitro reprogramming of fibroblasts into a pluripotent ES-cell-like state. Nature 448, 318–324 (2007)
Wernig, M. et al. A drug-inducible transgenic system for direct reprogramming of multiple somatic cell types. Nature Biotechnol. 26, 916–924 (2008)
Hanna, J. et al. Direct reprogramming of terminally differentiated mature B lymphocytes to pluripotency. Cell 133, 250–264 (2008)
Brambrink, T., Hochedlinger, K., Bell, G. & Jaenisch, R. ES cells derived from cloned and fertilized blastocysts are transcriptionally and functionally indistinguishable. Proc. Natl Acad. Sci. USA 103, 933–938 (2006)
Eggan, K. et al. Hybrid vigor, fetal overgrowth, and viability of mice derived by nuclear cloning and tetraploid embryo complementation. Proc. Natl Acad. Sci. USA 98, 6209–6214 (2001)
Nadin, B. M., Goodell, M. A. & Hirschi, K. K. Phenotype and hematopoietic potential of side population cells throughout embryonic development. Blood 102, 2436–2443 (2003)
Eden, S., Hashimshony, T., Keshet, I., Cedar, H. & Thorne, A. W. DNA methylation models histone acetylation. Nature 394, 842 (1998)
Chiu, C. P. & Blau, H. M. 5-Azacytidine permits gene activation in a previously noninducible cell type. Cell 40, 417–424 (1985)
Lengerke, C. et al. BMP and Wnt specify hematopoietic fate by activation of the Cdx-Hox pathway. Cell Stem Cell 2, 72–82 (2008)
Ball, M. P. et al. Targeted and genome-scale strategies reveal gene-body methylation signatures in human cells. Nature Biotechnol. 27, 361–368 (2009)
Kim, J. B. et al. Oct4-induced pluripotency in adult neural stem cells. Cell 136, 411–419 (2009)
Loh, Y. H. et al. Generation of induced pluripotent stem cells from human blood. Blood 113, 5476–5479 (2009)
Chin, M. H. et al. Induced pluripotent stem cells and embryonic stem cells are distinguished by gene expression signatures. Cell Stem Cell 5, 111–123 (2009)
Hanna, J. et al. Direct cell reprogramming is a stochastic process amenable to acceleration. Nature 462, 595–601 (2009)
Okita, K., Ichisaka, T. & Yamanaka, S. Generation of germline-competent induced pluripotent stem cells. Nature 448, 313–317 (2007)
Soldner, F. et al. Parkinson’s disease patient-derived induced pluripotent stem cells free of viral reprogramming factors. Cell 136, 964–977 (2009)
Stadtfeld, M. et al. Aberrant silencing of imprinted genes on chromosome 12qF1 in mouse induced pluripotent stem cells. Nature 465, 175–181 (2010)
Bernstein, B. E. et al. A bivalent chromatin structure marks key developmental genes in embryonic stem cells. Cell 125, 315–326 (2006)
Xu, J. et al. Transcriptional competence and the active marking of tissue-specific enhancers by defined transcription factors in embryonic and induced pluripotent stem cells. Genes Dev. 23, 2824–2838 (2009)
Osafune, K. et al. Marked differences in differentiation propensity among human embryonic stem cell lines. Nature Biotechnol. 26, 313–315 (2008)
Silva, J. et al. Promotion of reprogramming to ground state pluripotency by signal inhibition. PLoS Biol. 6, e253 (2008)
Polo, J. M. et al. Cell type of origin influences the molecular and functional properties of mouse induced pluripotent stem cells. Nature Biotechnol. 10.1038/nbt.1667 (19 July 2010)
Nomizu, T. et al. Determination of calcium content in individual biological cells by inductively coupled plasma atomic emission spectrometry. Anal. Chem. 66, 3000–3004 (1994)
Kirov, G. et al. Variation in the protocadherin γ A gene cluster. Genomics 82, 433–440 (2003)
Markoulaki, S. et al. Transgenic mice with defined combinations of drug-inducible reprogramming factors. Nature Biotechnol. 27, 169–171 (2009)
Koh, E. Y., Chen, T. & Daley, G. Q. Novel retroviral vectors to facilitate expression screens in mammalian cells. Nucleic Acids Res. 30, e142 (2002)
Conti, L. et al. Niche-independent symmetrical self-renewal of a mammalian tissue stem cell. PLoS Biol. 3, e283 (2005)
Schiedlmeier, B. et al. HOXB4’s road map to stem cell expansion. Proc. Natl Acad. Sci. USA 104, 16952–16957 (2007)
Pavlidis, P. & Noble, W. S. Analysis of strain and regional variation in gene expression in mouse brain. Genome Biol. 2, RESEARCH0042 (2001)
Acknowledgements
G.Q.D is an investigator of the Howard Hughes Medical Institute and was supported by NIH grants RO1-DK70055 and RO1-DK59279, and special funds received under the American Recovery and Reinvestment Act (RC2-HL102815). K.K. was supported by NIH (K99HL093212-01), LLS (3567-07) and Cooley’s Anemia Foundation. A.P.F was funded by NIH grants R37CA054358 and P50HG003233. I.L.W. was funded by NIH grants R01AI047457, R01AI047458, CA86065 and HL099999, and the Thomas and Stacey Siebel Foundation. L.I.R.E. was supported by a Special Fellow Career Development award from the Leukemia and Lymphoma Society. J.S. is supported by a fellowship from the California Institute for Regenerative Medicine (T1-00001). We acknowledge K. Hochedlinger for sharing his manuscript before publication.
Author information
Authors and Affiliations
Contributions
K.K. and G.Q.D. conceived the experimental plan. K.K., A.D., B.W., K.N., Z.R., H.J., L.I.R.E., A.Y., A.T., K.C.C., H.H., S.M.-F., O.N., T.J.Y., R.A.I., N.J., J.S., J.H. and P.M. performed the experiments. P.C., J.K. and M.J.A. performed statistical analysis. A.D., B.W. and A.P.F. performed CHARM and guided analysis of methylation. K.K., A.D., B.W., K.N., R.Z., P.C., J.K., M.J.A., H.J., T.J.Y., R.J., R.W., S.H.O., I.L.W., A.P.F. and G.Q.D. wrote the manuscript.
Corresponding authors
Ethics declarations
Competing interests
G.Q.D. is a member of the Scientific Advisory Boards of MPM Capital, Inc., Epizyme, Inc., and iPierian, Inc. R.J. is a member of the Scientific Advisory Boards of Fate Therapeutics, Inc. and StemGent, Inc. I.L.W is a member of the Scientific Advisory Boards of Cellerant, Inc, and Stem Cells, Inc.
Supplementary information
Supplementary Information
This file contains Supplementary Figures 1-13 with legends, Supplementary Tables 1-7 and References. (PDF 8512 kb)
Rights and permissions
About this article
Cite this article
Kim, K., Doi, A., Wen, B. et al. Epigenetic memory in induced pluripotent stem cells. Nature 467, 285–290 (2010). https://doi.org/10.1038/nature09342
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/nature09342
This article is cited by
-
In vitro erythrocyte production using human-induced pluripotent stem cells: determining the best hematopoietic stem cell sources
Stem Cell Research & Therapy (2023)
-
Comparison of gene expression between human and mouse iPSC-derived cardiomyocytes for stem cell therapies of cardiovascular defects via bioinformatic analysis
Translational Medicine Communications (2023)
-
Cell-type dependent regulation of pluripotency and chromatin remodeling genes by hydralazine
Stem Cell Research & Therapy (2023)
-
Vascular organoids: unveiling advantages, applications, challenges, and disease modelling strategies
Stem Cell Research & Therapy (2023)
-
A live-cell image-based machine learning strategy for reducing variability in PSC differentiation systems
Cell Discovery (2023)
Comments
By submitting a comment you agree to abide by our Terms and Community Guidelines. If you find something abusive or that does not comply with our terms or guidelines please flag it as inappropriate.